Whooping Cough Treatment Market size is poised to grow at substantial growth rate during the forecast period i.e., between 2024-2036. Whooping cough, also known as, pertussis, is a severe respiratory infection, common among children. The growth of the market can be attributed to the growing prevalence of whooping cough globally. According to the data by the World Health Organization (WHO), 151 074 cases of whooping cough were reported globally in 2018. The symptoms of whooping cough range from mild fever, runny nose and cough, to difficulty in breathing, whooping, and pneumonia. As the condition tends to be more severe for children, the rising pediatric population is estimated to boost the market growth. A report by the World Bank stated that the global population of children between 0 to 14 years reached 1.977 billion in 2020, up from 1.869 billion in 2010. Along with this, the growing health awareness among people, coupled with the adoption of advance treatment method, are anticipated to boost the market growth. Furthermore, high incidences of other lung and throat infections, including pharyngitis, and pneumonia, and rising pollution levels are also crucial factors supporting the growth of the market.
Growth Drivers
Challenges
The market is segmented by patient type into pediatric, adolescents, adults, and others, out of which, the pediatric segment is anticipated to hold a substantial share in the global whooping cough treatment market over the forecast period on account of high incidences and higher severity of whooping cough amongst children. Mostly in case of children, whooping cough results in pneumonia, which is a major cause of children mortality. As per a WHO report, pneumonia accounts for 14% of all deaths of children under 5 years old every year.
Our in-depth analysis of the global whooping cough treatment market includes the following segments:
|
By Patient Type |
|
|
By Drug Type |
|
|
By End User |
|
On the basis of geographical analysis, the global whooping cough treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is expected to dominate majority revenue share by 2036, ascribed to increasing pediatric population, along with growing availability of healthcare facilities in the developing regions, ascribed to increasing pediatric population, along with growing availability of healthcare facilities in the developing regions. Moreover, the high prevalence of whooping cough in countries, such as, India, China, Japan, Philippines, Vietnam, and others, is further estimated to boost the market growth. According to the data by WHO, 12,566 cases of pertussis were reported in India, while 2,947 cases were reported in Japan, in 2020. The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the advanced healthcare technologies present in the region, along with the presence of major pharmaceutical companies.
May 04, 2021: Teva Pharmaceutical Industries Ltd. announced the launch of its new Erythromycin tablets to treat or prevent a variety of bacterial infections.
February 27, 2020: GlaxoSmithKline plc (GSK) and Innoviva, Inc. announced the European Medicines Agency (EMA) approval of Trelegy Ellipta for the treatment of asthma in adults.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?